In recent clinical trials, blocking IL6 trans-signaling using the monoclonal antibody tocilizumab showed promising trends in patients with SSc (53), suggesting that IL6 might be a viable therapeutic target in SSc. Here, IL6 is linked to systemic sclerosis.